panitumumab
takeda,amgen,hlb bio group,jiangsu hengrui pharmaceuticals
['lba3505', 'triplet', 'triplete', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)']
interesting presentation by expert chiara cremolini! results from the phase 3 #triplete study.
intensification of upfront ct with #mfolfoxiri w/pan vs mfolfox6/pan in ras and braf wt mcrc pts did not result in improved orr. lba3505
#meded 
Independent and international experts in GI oncology supporting medical oncologists to give the best possible care to patients. Part of https://t.co/Y8pV8OaxOB